Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
CompanyDeals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
CompanyDeals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
CompanyDigital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

QYuns' QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
CompanyDeals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Leads Biolabs' Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
CompanyDrug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Company

WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities

CompanyDeals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

CompanyDeals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
CompanyDeals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Company

WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
CompanyDeals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

CompanyDrug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination